Cipla reports bigger-than-expected 11 percent increase in Q2 profit
Total revenue from operations increased 5 percent to 57.59 billion rupees.
Bengaluru: Indian drugmaker Cipla Ltd reported a bigger-than-expected 11% increase in second-quarter profit on Friday, helped by rising demand for its drugs and inhalers and a boost in its new ventures.
The company has been on an acquisition spree in recent months, from buying supplement maker Endura Mass to stake purchases in medical diagnostics firm Achira Labs and health tech company GoApptiv.
Cipla, which makes generic versions of respiratory drugs Advair and Albuterol, said consolidated net profit rose to 7.89 billion rupees ($95.6 million) in the quarter ended Sept. 30, from 7.11 billion rupees a year earlier.
Analysts, on average, had expected a profit of 7.83 billion rupees, according to Refinitiv data.
Total revenue from operations increased 5 percent to 57.59 billion rupees. Revenue from its mainstay pharmaceutical business rose 5 percent to 56.91 billion rupees, while revenue from new ventures doubled to 2.78 billion rupees.
Cipla said revenue from U.S. markets rose 25 percent to $179 million.
On Tuesday, Sun Pharmaceutical Industries Ltd, India's largest drugmaker, reported a surprise 10.5 percent rise in second-quarter profit, led by a surge in specialty drugs sales.
Cipla's shares were trading down 1.7 percent at 1,145 rupees as of 0955 GMT.
Read also: Dr Reddy's Labs, Cipla facilities join World Economic Forum Global Lighthouse Network
Next Story
